BONESUPPORT HOLDING AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 254.4 SEK | -.--% |
|
-1.24% | +35.18% |
| Apr. 25 | Transcript : Bonesupport Holding AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | Bonesupport Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 857M 81.41M | Sales 2025 * | 1.19B 113M | Capitalization | 16.72B 1.59B |
|---|---|---|---|---|---|
| Net income 2024 * | 174M 16.53M | Net income 2025 * | 311M 29.55M | EV / Sales 2024 * | 19.2 x |
| Net cash position 2024 * | 239M 22.71M | Net cash position 2025 * | 488M 46.37M | EV / Sales 2025 * | 13.7 x |
| P/E ratio 2024 * |
97.8
x | P/E ratio 2025 * |
53.5
x | Employees | 121 |
| Yield 2024 * |
-
| Yield 2025 * |
0.39% | Free-Float | 91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bonesupport Holding AB
More press releases
| 1 week | -1.24% | ||
| 1 month | +12.57% | ||
| 3 months | +24.58% | ||
| 6 months | +45.79% | ||
| Current year | +35.18% |
1 week
241.00
266.60
1 month
216.20266.60
Current year
172.50266.60
1 year
110.20266.60
3 years
34.20266.60
5 years
19.05266.60
10 years
9.04266.60
| Managers | Title | Age | Since |
|---|---|---|---|
Emil Billbäck
CEO | Chief Executive Officer | 54 | 18-02-28 |
Hakan Johansson
DFI | Director of Finance/CFO | 61 | 18-10-31 |
| Chief Operating Officer | - | 21-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | - | |
| Chairman | 69 | 17-02-28 | |
| Director/Board Member | 68 | 16-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.75% | 5 M€ | +15.85% | ||
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 254.4 | -.--% | 1,243,855 |
| 24-05-30 | 254.4 | +3.00% | 137,327 |
| 24-05-29 | 247 | -0.72% | 90,287 |
| 24-05-28 | 248.8 | -3.72% | 223,965 |
| 24-05-27 | 258.4 | +0.31% | 91,318 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:29 am EDT
More quotes
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Sector
Pharmaceuticals
Calendar
2024-07-11
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
254.4
SEK
Average target price
292.7
SEK
Spread / Average Target
+15.04%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +35.18% | 1.59B | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B |
- Stock Market
- Equities
- BONEX Stock
